scRNA-seq and scATAC-seq Data Analysis
Learn More Understanding transcription signals at the individual cell resolution is fundamental to our understanding of more complex biological systems such
Predicting Gene Expression Using Millions of Random Promoter Sequences
Learn More Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in
Crowd-Sourcing and Open Science
The DREAM Directors published a post on the FEBS Network headlined "Can crowd-sourcing help advance open science?" The article outlines some benefits
Anti-PD1 Response Prediction Dream Challenge
LEARN MORE While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1
Winners of the $25,000 BEAT-PD DREAM Challenge Announced
NEW YORK (June 17, 2020) – The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Sage Bionetworks announce the winners of
COVID-19 EHR DREAM Challenge
LEARN MORE The rapid rise of COVID-19 has challenged healthcare globally. Due to the importance and emergent need for better understanding
CTD2 Chemosensitivity DREAM Challenge
Learn More The Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves
Combining Artificial Intelligence with Assessments from Radiologists Could Help Improve Accuracy of Mammography Screenings
SEATTLE, March 2, 2020 – In a study published today in the journal JAMA Network Open, researchers demonstrated that machine-learning algorithms could
Metadata Automation DREAM Challenge
Learn More We aim to significantly lower the burden of adding coherent metadata annotations across the data ecosystem to streamline and
BEAT-PD DREAM Challenge
Learn More Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for quantitative, remote monitoring of health
CTD^2 BeatAML DREAM Challenge
Learn More The goal of the Beat AML DREAM Challenge is to define patient subpopulations tailored to individual treatments by discovering
CTD^2 Pancancer Drug Activity DREAM Challenge
Learn More Over the course of two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a
Subscribe to our Newsletter